The HIV pandemic has since the 1980’s been responsibly for 35 million deaths across the globe. South Africa bears a particularly heave burden when it comes to the disease with 5.7 million cases as of 2017. A key local issue is the need for affordable anti-retroviral’s for the management of the disease, unfortunately, a lack of local manufacturing has meant that afflicted South Africans often suffer with demand often outweighing supply. Betty’s research involves process development for the anti-HIV drugs tenofovir diisoproxil and tenofovir alenfanamide where she aims to develop more economical routes to these critical pharmaceuticals utilising both traditional batch and flow techniques.

Contact details

 

Email: betty.g.kwati@gmail.com

Linkedin:

ResearchGate: 

 

Supervisor:

Dr Darren Riley